Cargando…
Use of artificial intelligence to assess the risk of coronary artery disease without additional (non-invasive) testing: validation in a low-risk to intermediate-risk outpatient clinic cohort
OBJECTIVES: Predicting the presence or absence of coronary artery disease (CAD) is clinically important. Pretest probability (PTP) and CAD consortium clinical (CAD2) model and risk scores used in the guidelines are not sufficiently accurate as the only guidance for applying invasive testing or disch...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9516207/ https://www.ncbi.nlm.nih.gov/pubmed/36167368 http://dx.doi.org/10.1136/bmjopen-2021-055170 |
_version_ | 1784798658114355200 |
---|---|
author | Eurlings, Casper G M J Bektas, Sema Sanders-van Wijk, Sandra Tsirkin, Andrew Vasilchenko, Vasily Meex, Steven J R Failer, Michael Oehri, Caroline Ruff, Peter Zellweger, Michael J Brunner-La Rocca, Hans-Peter |
author_facet | Eurlings, Casper G M J Bektas, Sema Sanders-van Wijk, Sandra Tsirkin, Andrew Vasilchenko, Vasily Meex, Steven J R Failer, Michael Oehri, Caroline Ruff, Peter Zellweger, Michael J Brunner-La Rocca, Hans-Peter |
author_sort | Eurlings, Casper G M J |
collection | PubMed |
description | OBJECTIVES: Predicting the presence or absence of coronary artery disease (CAD) is clinically important. Pretest probability (PTP) and CAD consortium clinical (CAD2) model and risk scores used in the guidelines are not sufficiently accurate as the only guidance for applying invasive testing or discharging a patient. Artificial intelligence without the need of additional non-invasive testing is not yet used in this context, as previous results of the model are promising, but available in high-risk population only. Still, validation in low-risk patients, which is clinically most relevant, is lacking. DESIGN: Retrospective cohort study. SETTING: Secondary outpatient clinic care in one Dutch academic hospital. PARTICIPANTS: We included 696 patients referred from primary care for further testing regarding the presence or absence of CAD. The results were compared with PTP and CAD2 using receiver operating characteristic (ROC) curves (area under the curve (AUC)). CAD was defined by a coronary stenosis >50% in at least one coronary vessel in invasive coronary or CT angiography, or having a coronary event within 6 months. OUTCOME MEASURES: The first cohort validating the memetic pattern-based algorithm (MPA) model developed in two high-risk populations in a low-risk to intermediate-risk cohort to improve risk stratification for non-invasive diagnosis of the presence or absence of CAD. RESULTS: The population contained 49% male, average age was 65.6±12.6 years. 16.2% had CAD. The AUCs of the MPA model, the PTP and the CAD2 were 0.87, 0.80, and 0.82, respectively. Applying the MPA model resulted in possible discharge of 67.7% of the patients with an acceptable CAD rate of 4.2%. CONCLUSIONS: In this low-risk to intermediate-risk population, the MPA model provides a good risk stratification of presence or absence of CAD with a better ROC compared with traditional risk scores. The results are promising but need prospective confirmation. |
format | Online Article Text |
id | pubmed-9516207 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-95162072022-09-29 Use of artificial intelligence to assess the risk of coronary artery disease without additional (non-invasive) testing: validation in a low-risk to intermediate-risk outpatient clinic cohort Eurlings, Casper G M J Bektas, Sema Sanders-van Wijk, Sandra Tsirkin, Andrew Vasilchenko, Vasily Meex, Steven J R Failer, Michael Oehri, Caroline Ruff, Peter Zellweger, Michael J Brunner-La Rocca, Hans-Peter BMJ Open Cardiovascular Medicine OBJECTIVES: Predicting the presence or absence of coronary artery disease (CAD) is clinically important. Pretest probability (PTP) and CAD consortium clinical (CAD2) model and risk scores used in the guidelines are not sufficiently accurate as the only guidance for applying invasive testing or discharging a patient. Artificial intelligence without the need of additional non-invasive testing is not yet used in this context, as previous results of the model are promising, but available in high-risk population only. Still, validation in low-risk patients, which is clinically most relevant, is lacking. DESIGN: Retrospective cohort study. SETTING: Secondary outpatient clinic care in one Dutch academic hospital. PARTICIPANTS: We included 696 patients referred from primary care for further testing regarding the presence or absence of CAD. The results were compared with PTP and CAD2 using receiver operating characteristic (ROC) curves (area under the curve (AUC)). CAD was defined by a coronary stenosis >50% in at least one coronary vessel in invasive coronary or CT angiography, or having a coronary event within 6 months. OUTCOME MEASURES: The first cohort validating the memetic pattern-based algorithm (MPA) model developed in two high-risk populations in a low-risk to intermediate-risk cohort to improve risk stratification for non-invasive diagnosis of the presence or absence of CAD. RESULTS: The population contained 49% male, average age was 65.6±12.6 years. 16.2% had CAD. The AUCs of the MPA model, the PTP and the CAD2 were 0.87, 0.80, and 0.82, respectively. Applying the MPA model resulted in possible discharge of 67.7% of the patients with an acceptable CAD rate of 4.2%. CONCLUSIONS: In this low-risk to intermediate-risk population, the MPA model provides a good risk stratification of presence or absence of CAD with a better ROC compared with traditional risk scores. The results are promising but need prospective confirmation. BMJ Publishing Group 2022-09-26 /pmc/articles/PMC9516207/ /pubmed/36167368 http://dx.doi.org/10.1136/bmjopen-2021-055170 Text en © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Cardiovascular Medicine Eurlings, Casper G M J Bektas, Sema Sanders-van Wijk, Sandra Tsirkin, Andrew Vasilchenko, Vasily Meex, Steven J R Failer, Michael Oehri, Caroline Ruff, Peter Zellweger, Michael J Brunner-La Rocca, Hans-Peter Use of artificial intelligence to assess the risk of coronary artery disease without additional (non-invasive) testing: validation in a low-risk to intermediate-risk outpatient clinic cohort |
title | Use of artificial intelligence to assess the risk of coronary artery disease without additional (non-invasive) testing: validation in a low-risk to intermediate-risk outpatient clinic cohort |
title_full | Use of artificial intelligence to assess the risk of coronary artery disease without additional (non-invasive) testing: validation in a low-risk to intermediate-risk outpatient clinic cohort |
title_fullStr | Use of artificial intelligence to assess the risk of coronary artery disease without additional (non-invasive) testing: validation in a low-risk to intermediate-risk outpatient clinic cohort |
title_full_unstemmed | Use of artificial intelligence to assess the risk of coronary artery disease without additional (non-invasive) testing: validation in a low-risk to intermediate-risk outpatient clinic cohort |
title_short | Use of artificial intelligence to assess the risk of coronary artery disease without additional (non-invasive) testing: validation in a low-risk to intermediate-risk outpatient clinic cohort |
title_sort | use of artificial intelligence to assess the risk of coronary artery disease without additional (non-invasive) testing: validation in a low-risk to intermediate-risk outpatient clinic cohort |
topic | Cardiovascular Medicine |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9516207/ https://www.ncbi.nlm.nih.gov/pubmed/36167368 http://dx.doi.org/10.1136/bmjopen-2021-055170 |
work_keys_str_mv | AT eurlingscaspergmj useofartificialintelligencetoassesstheriskofcoronaryarterydiseasewithoutadditionalnoninvasivetestingvalidationinalowrisktointermediateriskoutpatientcliniccohort AT bektassema useofartificialintelligencetoassesstheriskofcoronaryarterydiseasewithoutadditionalnoninvasivetestingvalidationinalowrisktointermediateriskoutpatientcliniccohort AT sandersvanwijksandra useofartificialintelligencetoassesstheriskofcoronaryarterydiseasewithoutadditionalnoninvasivetestingvalidationinalowrisktointermediateriskoutpatientcliniccohort AT tsirkinandrew useofartificialintelligencetoassesstheriskofcoronaryarterydiseasewithoutadditionalnoninvasivetestingvalidationinalowrisktointermediateriskoutpatientcliniccohort AT vasilchenkovasily useofartificialintelligencetoassesstheriskofcoronaryarterydiseasewithoutadditionalnoninvasivetestingvalidationinalowrisktointermediateriskoutpatientcliniccohort AT meexstevenjr useofartificialintelligencetoassesstheriskofcoronaryarterydiseasewithoutadditionalnoninvasivetestingvalidationinalowrisktointermediateriskoutpatientcliniccohort AT failermichael useofartificialintelligencetoassesstheriskofcoronaryarterydiseasewithoutadditionalnoninvasivetestingvalidationinalowrisktointermediateriskoutpatientcliniccohort AT oehricaroline useofartificialintelligencetoassesstheriskofcoronaryarterydiseasewithoutadditionalnoninvasivetestingvalidationinalowrisktointermediateriskoutpatientcliniccohort AT ruffpeter useofartificialintelligencetoassesstheriskofcoronaryarterydiseasewithoutadditionalnoninvasivetestingvalidationinalowrisktointermediateriskoutpatientcliniccohort AT zellwegermichaelj useofartificialintelligencetoassesstheriskofcoronaryarterydiseasewithoutadditionalnoninvasivetestingvalidationinalowrisktointermediateriskoutpatientcliniccohort AT brunnerlaroccahanspeter useofartificialintelligencetoassesstheriskofcoronaryarterydiseasewithoutadditionalnoninvasivetestingvalidationinalowrisktointermediateriskoutpatientcliniccohort |